JP2023527049A5 - - Google Patents
Info
- Publication number
- JP2023527049A5 JP2023527049A5 JP2022572753A JP2022572753A JP2023527049A5 JP 2023527049 A5 JP2023527049 A5 JP 2023527049A5 JP 2022572753 A JP2022572753 A JP 2022572753A JP 2022572753 A JP2022572753 A JP 2022572753A JP 2023527049 A5 JP2023527049 A5 JP 2023527049A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- fewer
- residues
- amino acid
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2007842.4 | 2020-05-26 | ||
| GBGB2007842.4A GB202007842D0 (en) | 2020-05-26 | 2020-05-26 | Polypeptide useful in adoptive cell therapy |
| PCT/EP2021/064053 WO2021239812A1 (en) | 2020-05-26 | 2021-05-26 | Polypeptide useful in adoptive cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527049A JP2023527049A (ja) | 2023-06-26 |
| JP2023527049A5 true JP2023527049A5 (cg-RX-API-DMAC7.html) | 2024-05-29 |
Family
ID=71406309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572753A Pending JP2023527049A (ja) | 2020-05-26 | 2021-05-26 | 養子細胞療法に有用なポリペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230183311A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4157318A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527049A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115955977A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021279184A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179441A1 (cg-RX-API-DMAC7.html) |
| GB (2) | GB202007842D0 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202210503A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021239812A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227756B2 (en) | 2018-04-18 | 2025-02-18 | Ucl Business Ltd | Engineered regulatory T cell |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| US20250017967A1 (en) | 2021-12-17 | 2025-01-16 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4496883A1 (en) | 2022-03-22 | 2025-01-29 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| EP4519294A1 (en) * | 2022-05-04 | 2025-03-12 | Earli Inc. | Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194649A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t cells and uses thereof |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| EP4442322A1 (en) | 2023-04-06 | 2024-10-09 | Medizinische Hochschule Hannover | Liver-specific car for use against immunologic rejection |
| CN121586727A (zh) | 2023-06-21 | 2026-02-27 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| EP4766382A1 (en) | 2023-08-24 | 2026-07-01 | Medizinische Hochschule Hannover | BECAUSE FOR THE TREATMENT OF MS OR MA |
| EP4512415A1 (en) | 2023-08-24 | 2025-02-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| EP4678187A1 (en) | 2024-07-11 | 2026-01-14 | Medizinische Hochschule Hannover | Compound for use in the treatment of inflammatory bowel disease |
| WO2026027876A1 (en) | 2024-07-29 | 2026-02-05 | Quell Therapeutics Limited | Chimeric antigen receptor |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2528595A1 (en) | 2003-06-13 | 2005-01-06 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| KR20080039844A (ko) | 2005-05-24 | 2008-05-07 | 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 | B―세포 림프종 치료를 위한 cd20에 대한 모노클로날항체의 제조 방법 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201415344D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| TWI700298B (zh) * | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向b細胞成熟抗原之嵌合型抗原受體類 |
| US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| CN110869046B (zh) * | 2017-03-31 | 2025-02-25 | 塞勒克提斯公司 | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 |
| MX2020010808A (es) * | 2018-04-13 | 2021-03-02 | Sangamo Therapeutics France | Receptor de antigeno quimerico especifico para el receptor de interleucina-23. |
| CN112996819B (zh) * | 2018-08-16 | 2025-11-04 | 纪念斯隆-凯特琳癌症中心 | 细胞分选系统及使用方法 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
-
2020
- 2020-05-26 GB GBGB2007842.4A patent/GB202007842D0/en not_active Ceased
-
2021
- 2021-05-26 WO PCT/EP2021/064053 patent/WO2021239812A1/en not_active Ceased
- 2021-05-26 GB GB2218768.6A patent/GB2611448B/en active Active
- 2021-05-26 JP JP2022572753A patent/JP2023527049A/ja active Pending
- 2021-05-26 CA CA3179441A patent/CA3179441A1/en active Pending
- 2021-05-26 US US17/926,374 patent/US20230183311A1/en not_active Abandoned
- 2021-05-26 EP EP21728234.2A patent/EP4157318A1/en not_active Withdrawn
- 2021-05-26 CN CN202180047478.8A patent/CN115955977A/zh active Pending
- 2021-05-26 TW TW110118988A patent/TW202210503A/zh unknown
- 2021-05-26 AU AU2021279184A patent/AU2021279184A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| AU2018298881B2 (en) | Improved dual specificity polypeptide molecule | |
| KR102174280B1 (ko) | 키메라 항원 수용체 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| AU2019205273B2 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| JP6936497B2 (ja) | 多価Fv抗体 | |
| CA2811734C (en) | Multimeric il-15 soluble fusion molecules and methods of making and using same | |
| JP2022534680A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527310A5 (cg-RX-API-DMAC7.html) | ||
| KR20220025698A (ko) | 다기능 융합 단백질 및 이의 용도 | |
| CN111801347A (zh) | Ctla-4变体免疫调节蛋白和其用途 | |
| JP2022545815A5 (cg-RX-API-DMAC7.html) | ||
| JP2024534783A5 (cg-RX-API-DMAC7.html) | ||
| RU2815388C2 (ru) | Многофункциональные слитые белки и их применения | |
| KR20260042160A (ko) | 이중특이적 폴리펩티드 분자 | |
| WO2022026577A4 (en) | Chimeric t cell receptors, nucleic acids, and methods of making and using the same | |
| HK40003407B (en) | Improved dual specificity polypeptide molecule | |
| HK40003407A (en) | Improved dual specificity polypeptide molecule | |
| HK40029654B (en) | Improved dual specificity polypeptide molecule | |
| HK40029654A (en) | Improved dual specificity polypeptide molecule | |
| IL272045B2 (en) | A polypeptide molecule with dual-purpose specificity |